Delisting riskPopularity #4,127
Lexaria Bioscience (LEXX)
Developer and licensor of DehydraTECH oral drug-delivery technology.
$3.36
After-hours close+0.17 (+5.33%)
At close$3.19(−6.86%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 6.62% | 109.4K shares | |
|---|---|---|---|
| 31 holders · as of Jun 30, 2026 | |||
| Insiders | 2.65% | 43.9K shares | |
| 6 holders · as of Mar 18, 2026 | |||
| Other | 90.73% | 1.50M shares | |
| remainder | |||
1.65M company shares as of Sep 9, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
31 holders · 1.64M shares · 6 new positions · 16 increased · 6 reduced · 3 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Invenomic Capital Management LP | 345.7K | 20.92% | −96.6K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 298.4K | 18.06% | +76.1K | Aug 13, 2026 |
| Geode Capital Management, LLC | 250.4K | 15.15% | −43.7K | Aug 12, 2026 |
| Citadel Advisors LLC | 156.9K | 9.50% | +143.4K | Sep 2, 2026 |
| Toronto Dominion Bank | 100.0K | 6.05% | −40.0K | Aug 14, 2026 |
| Vanguard Fiduciary Trust Co | 94.2K | 5.70% | 0 | Aug 13, 2026 |
| HRT Financial LP | 65.0K | 3.94% | +46.6K | Aug 14, 2026 |
| UBS Group AG | 47.0K | 2.84% | −5.7K | Aug 13, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.